Gland Pharma gets EIR for Pashamylaram Facility

24 Nov 2023 Evaluate

Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA indicating closure of the inspection at Pashamylaram Facility, Hyderabad. The Pre-Market Inspection covering USFDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) by USFDA conducted at the Company’s Pashamylaram Facility at Hyderabad between August 23, 2023 and August 26, 2023.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1709.10 -18.85 (-1.09%)
30-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.30
Dr. Reddys Lab 6198.90
Cipla 1402.20
Zydus Lifesciences 957.00
Lupin 1645.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.